BCAS2 Antibody
| Code | Size | Price |
|---|
| PSI-5627-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5627-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
BCAS2 Antibody: DAM1, SPF27, Snt309, DAM1, Pre-mRNA-splicing factor SPF27, Breast carcinoma-amplified sequence 2
Application Note:
BCAS2 antibody can be used for detection of BCAS2 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
BCAS2 Antibody: BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53-null or -mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.
Background References:
- Nagasaki K, Maass N, Manabe T, et al. Identification of a novel gene, DAM1, amplified at chromosome 1p13.3-21 region in human breast cancer cell lines. Cancer Lett.1999; 140:219-26.
- Qi C, Zhu YT, Chang J, et al. Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence Biochem. Biophys. Res. Commun.2005; 328:393-8.
- Huo PC, Tsao YP, Chang HW, et al. Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res.2009; 69:8877-85.
Buffer:
BCAS2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
BCAS2 antibody was raised against a 14 amino acid synthetic peptide near the carboxy terminus of human BCAS2.
The immunogen is located within the last 50 amino acids of BCAS2.
The immunogen is located within the last 50 amino acids of BCAS2.
NCBI Gene ID #:
10286
NCBI Official Name:
breast carcinoma amplified sequence 2
NCBI Official Symbol:
BCAS2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
CAG46834
Protein GI Number:
49457027
Purification:
BCAS2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
Swissprot #:
O75934
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | BCAS2 Peptide | PSI-5627P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|